Your browser doesn't support javascript.
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.
Inada, Makoto; Ishikane, Masahiro; Terada, Mari; Matsunaga, Akihiro; Maeda, Kenji; Iwamoto, Noriko; Ujiie, Mugen; Kutsuna, Satoshi; Morioka, Shinichiro; Ishizaka, Yukihito; Mitsuya, Hiroaki; Ohmagari, Norio.
  • Inada M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ishikane M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ishikanemasahiro@gmail.com.
  • Terada M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan.
  • Matsunaga A; Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Maeda K; Department of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Iwamoto N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ujiie M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kutsuna S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Professor, Department of Infection Control, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Morioka S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ishizaka Y; Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Vice Director General, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Mitsuya H; Department of Refractory Viral Infections, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Director General, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Int J Infect Dis ; 119: 18-20, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1889466
ABSTRACT
We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and neutralizing activity from the first infection before and after 2 doses of vaccine. Both antispike IgG titer and neutralizing activity showed a tendency to decline almost 1 year after initial infection; they rapidly increased after the first vaccination, and they remained high after the second vaccination. Although this is a single case report, it seems to have generalizability because the findings are consistent with previous reports regarding single infections or 3 doses of vaccination. Our findings suggest that a single booster shot may provide sufficient protection and aid the understanding of immunologic responses of vaccination in patients with COVID-19 with history of re-infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Case report / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans / Male / Middle aged Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2022.03.017

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Case report / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans / Male / Middle aged Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2022.03.017